The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Anticancer drug targets: cell cycle and checkpoint control
Open accessAbstract
Components of the cell cycle machinery are frequently altered in human cancer. Central players are the cyclin-dependent kinases (cdks), which govern the initiation, progression, and completion of cell cycle events. The scheduled activity of the cdks, which allows orderly transition between cell cycle phases, is controlled by their association with cyclins and cdk inhibitors, by their state of phosphorylation, and by ubiquitin-mediated proteolysis. As malignant cells evolve, both genetic and epigenetic mechanisms commonly affect the expression of cell cycle regulatory proteins, causing overexpression of cyclins and loss of expression of cdk inhibitors. A major consequence is deregulated cdk activity, providing cells with a selective growth advantage. The crucial role of the cdks has prompted great interest in the development of specific kinase inhibitors that would be expected to block cell cycle progression and induce growth arrest. Another hallmark of the transformed state is incompetent checkpoint control, resulting in aberrant responses to cellular damage. For example, damage to DNA or the spindle apparatus normally triggers cell cycle arrest or apoptosis, depending on the degree of damage and the cellular context. Cell cycle arrest most frequently occurs at the G1/S or G2/M boundaries. When checkpoint arrest control is compromised, initiation of S phase or mitosis occurs despite cellular damage, and the ensuing genetic instability may lead to the eventual emergence of a malignant clone. However, this failure of cell cycle arrest responses in malignant cells can also be exploited therapeutically. Cells in which checkpoint control is disrupted are more sensitive to additional genotoxic or microtubular damage. Unbridled cell cycle progression in the presence of such damage is usually lethal, which may explain the selective sensitivity of some cancer cells to DNA-damaging treatments. For this reason, intact components of cell cycle arrest checkpoints are also potential targets for novel antineoplastics, and their inhibition may increase the sensitivity of tumor cells to standard chemotherapy and radiation (1). Many of the compounds under study as anti-tumor agents act at multiple steps in the cell cycle, and their effects may be cytostatic or cytotoxic, depending on the cell cycle status of the target cells. Hence, an understanding of the molecular interactions involved may suggest ways to sensitize cells to the effects of these compounds. In particular, combinations of drugs, applied in a specific sequence, may be used to maneuver a tumor cell population into a state where it is most susceptible to the cytotoxic effects of novel, or indeed traditional, chemotherapeutic agents. Here, we review key aspects of cell cycle and checkpoint control, as well as exploitable abnormalities commonly found in cancer, in order to focus on promising targets of new agents presently in clinical trial or under development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
Harbour, J. W., Luo, R. X., Santi, A. D., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)81519-6 · Cited by 1,057
(1999) · PubMed · Cited by 1,030
14-3-3σ is required to prevent mitotic catastrophe after DNA damage
Chan, T. A., Hermeking, H., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Nature · doi:10.1038/44188 · Cited by 895
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
Waldman, T., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1996) · Nature · doi:10.1038/381713a0 · Cited by 728
Carlson, B. A., Dubay, M., Sausville, E. A., Brizuela, L., & Worland, P. J. (1996) · PubMed · Cited by 580
Cited by
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Protein Kinase Inhibitors: Insights into Drug Design from Structure
Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,198
Mechanism-Based Target Identification and Drug Discovery in Cancer Research
Gibbs, J. B. (2000) · Science · doi:10.1126/science.287.5460.1969 · Cited by 606
An overview on the role of dietary phenolics for the treatment of cancers
Anantharaju, P. G., Gowda, P. C., Vimalambike, M. G., & Madhunapantula, S. V. (2016) · Nutrition Journal · doi:10.1186/s12937-016-0217-2 · Cited by 517
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513
DNA damage checkpoint kinases in cancer
Smith, H. L., Southgate, H., Tweddle, D. A., & Curtin, N. J. (2020) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2020.3 · Cited by 322
The Molecular and Genetic Basis of Neurological Tumours
Zhu, Y., & Parada, L. F. (2002) · Nature Reviews Cancer · doi:10.1038/nrc866 · Cited by 309
Abuetabh, Y., Wu, H. H., Chai, C., Al Yousef, H., Persad, S., Sergi, C. M., & Leng, R. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00863-4 · Cited by 272
Li, Y., Tan, C.-P., Zhang, W., He, L., Ji, L.-N., & Mao, Z.-W. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.070 · Cited by 267
Oh, J.-M., Choi, S.-J., Kim, S.-T., & Choy, J.-H. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0601323 · Cited by 254
Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?
Rixe, O., & Fojo, T. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2141 · Cited by 147
Lopes, E. C., Valls, E., Figueroa, M. E., Mazur, A., Meng, F.-G., Chiosis, G., Laird, P. W., Schreiber-Agus, N., Greally, J. M., Prokhortchouk, E., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0344 · Cited by 119
“mediated cellular checkpoints contributes to tumor cell resistance to chemotherapy (27).”
BackgroundWnt Signaling in Renal Cell Carcinoma
Xu, Q., Krause, M., Samoylenko, A., & Vainio, S. (2016) · Cancers · doi:10.3390/cancers8060057 · Cited by 99
Liu, X., Yang, J., Zhang, Y., Fang, Y., Wang, F., Wang, J., Zheng, X., & Yang, J. (2016) · Scientific Reports · doi:10.1038/srep22811 · Cited by 63
Metadata
- Authors
- Shapiro, G. I., & Harper, J. W.
- Venue
- Journal of Clinical Investigation
- Published
- 1999-12-15
- Volume
- 104
- Issue
- 12
- Pages
- 1645-1653
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2014613601
- Cited by
- 464
- References
- 40
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.